ANKHD1 and plasma cell myeloma: In human multiple myeloma cell lines, ANKHD1 can act on the promoter region of the cyclin-dependent kinase inhibitor p21 to upregulate the proliferation of multiple myeloma cells and affect the cell cycle progression [44].